

THE PATHS TO A CURE

2014 ANNUAL REPORT



Alzheimer's
Drug Discovery
Foundation

The Alzheimer's Drug Discovery Foundation's mission is to rapidly accelerate the discovery of drugs to prevent, treat and cure Alzheimer's disease.

BOARD OF GOVERNORS

HONORARY CHAIRMAN

Justice Sandra Day O'Connor

CO-CHAIRMEN

Leonard A. Lauder
Ronald S. Lauder

VICE CHAIRMAN

Randal Sandler

Robert Appel*
Robert A. Belfer
Nancy Corzine**
Lady Lynn Forester de Rothschild
Bonnie Pfeifer Evans
Melvin R. Goodes
Nancy Goodes
Laurence C. Leeds
Thomas F. McWilliams
Alice Shure
Peter J. Solomon
Sally Susman
Paula Zahn

EX OFFICIO

Howard Fillit, MD

OFFICERS

Lisa Somar, *Assistant Treasurer and Secretary*
Kevin Dieterich, *Treasurer*

* Appointed in 2015

**Past Board President

BOARD OF OVERSEERS

CO-CHAIRMEN

Sharon T. Sager
Randal Sandler

Carol Seabrook Boulanger
Charles Cangro
Faith Perlmutter Diamond
Mitchell D. Eichen
Allan M. Green, MD, PhD, JD
Christopher Johnson
Elise Gelman Lefkowitz
Philip Lovett
Emilio Matt
Pamela J. Newman
Phebe Farrow Port
John Scully*
Mary Rose Taylor
Alison Zaino
Linda S. Zambelli

TOGETHER WE CAN CONQUER ALZHEIMER'S DISEASE

Dear Friends,

More than 44 million people worldwide suffer from Alzheimer's disease and related dementias—and there remains no way to cure or even slow the progress of this devastating illness. **But there is hope in drug discovery.**

The Alzheimer's Drug Discovery Foundation (ADDF) is supporting scientists around the globe who are investigating novel drugs to prevent, treat and cure Alzheimer's disease. Thanks to your generous contributions, these researchers are making remarkable progress.

With your continued support, they can take the steps necessary to bring forth a cure for this devastating disease.

Together we can and will conquer Alzheimer's disease.

With our deepest thanks,



Leonard A. Lauder
LEONARD A. LAUDER
Co-Chairman and Co-Founder




Ronald S. Lauder
RONALD S. LAUDER
Co-Chairman and Co-Founder

A DIVERSIFIED PORTFOLIO OF ALZHEIMER'S DRUG TARGETS

Will the first disease-modifying drug for Alzheimer's work by minimizing inflammation in the brain? Or will it protect neurons from damage and death? While researchers have a number of promising hypotheses, they do not yet know which Alzheimer's drug target will ultimately offer the greatest benefit to the largest number of patients.

That's why we are investing in a diverse portfolio of therapeutic approaches. We feature projects using several of these approaches in this Annual Report. By spreading our funding across a number of potential drug targets, we increase the likelihood of identifying an effective treatment—and ultimately a cure—for Alzheimer's disease.



*Data represents the Alzheimer's Drug Discovery Foundation's investments from 1999 through 2014.

DEAR FRIENDS,

Thanks to your continued generosity, the Alzheimer's Drug Discovery Foundation was able to support a diverse array of Alzheimer's research in 2014. Over the course of the year, we awarded 35 new grants to scientists who have already made tremendous progress in their search for effective drugs to prevent, treat and cure this devastating disease. In total, our team is actively managing 125 scientific programs.

While our funded investigators share a common goal, they are pursuing different therapeutic strategies. There are many hypotheses for drug discovery in Alzheimer's disease, and the scientists we support are exploring a multitude of these. Today, most researchers believe that we'll need more than one drug to tackle Alzheimer's disease. Like with heart disease—which can require a combination of drugs to lower cholesterol, reduce blood pressure and prevent blood clots—overcoming Alzheimer's will likely involve a multi-pronged approach to prevention and treatment.

Our research funding is strategically positioned across a diverse portfolio to increase the odds of developing effective treatments for Alzheimer's. In 2014, our investment choices included:

- More drug discovery and development science than ever before, with \$9.6 million in Alzheimer's drug investments.
- Increased investment in Alzheimer's clinical trials, recognizing that research in the field is rapidly advancing and that the need to test new drugs in humans is urgent.



LETTER FROM HOWARD FILLIT, MD

Founding Executive Director and Chief Science Officer


- More funding for clinical trials of existing and approved drugs through repurposing, which can reach patients more quickly and at a lower cost.
- Increased investment in innovative, entrepreneurial biotechnology companies.
- Development of critical educational and networking resources for researchers, ensuring that they have the tools and partners they need to share ideas, contract work and further their expertise.
- Launch of Cognitive Vitality, an online resource that empowers people to protect their aging brain.

In this Annual Report, you will learn even more about the groundbreaking research your generous donations make possible. Your investment in the ADDF and our network of dedicated scientists means that the 44 million people worldwide living with Alzheimer's and the millions more who love them have hope.

As always, thank you for the privilege of working with you to accelerate the development of effective drugs for Alzheimer's disease.

Sincerely,

Howard



OUR ALZHEIMER'S ARMY

In a lab in northern England, Dr. Christian Holscher unpacks new laboratory equipment and carefully inspects the pieces. Dr. Holscher and his team, who are based at Lancaster University, are preparing to investigate whether two experimental diabetes drugs could help prevent the onset of Alzheimer's disease. If the results of their trial are successful, the most promising of these repurposed drugs could be available to patients with Alzheimer's disease in the next three to five years.

Dr. Holscher is one of 35 grantees working in Europe, the U.S., and Canada, who received funding from the Alzheimer's Drug Discovery Foundation in 2014. These researchers—whose projects were vetted by panels of leading experts in Alzheimer's drug discovery and development—represent some of the best and brightest scientific minds in the world.

In the pages that follow, we'll introduce you to some of our grantees and the research projects they are driving forward. You can rest assured knowing that these leading Alzheimer's scientists are doing everything in their power to end this devastating disease—work that would be impossible without your ongoing support.

“It's impossible to travel in life and not meet people who have a family story to tell about Alzheimer's.”



MARTIN JEFSON, MD
RODIN THERAPEUTICS

Martin Jefson, PhD, says of his work in Alzheimer's research, “I find it fascinating for all the reasons that most people do. It's a disorder with a high unmet need. It's a disease with high economic, social and familial costs.”

But he's also intrigued by Alzheimer's for purely scientific reasons. “It's an absorbing and challenging scientific problem,” Dr. Jefson says. “It's a classical drug discovery and development opportunity. That is my training and my passion.”

Dr. Jefson is using that training to test the safety and usefulness of a new treatment for Alzheimer's disease in animal models. The drug, designed to improve brain function and cognition, works through epigenetic mechanisms. It's a pioneering approach to treating Alzheimer's, affecting changes in brain function by modifying gene expression and protein levels.

“Funding from the Alzheimer's Drug Discovery Foundation has been critical to our work,” Dr. Jefson says. “It allowed us to transition from in vitro studies to animal experiments.”

There are currently no other drugs under study to treat cognitive impairment that work through epigenetic mechanisms. It's not entirely uncharted territory, however. There are now drugs for cancer and other diseases that work similarly.

NEUROPROTECTION

As Alzheimer's disease progresses, neurons (or nerve cells) lose their connections and begin to die, causing the loss of memory and other essential cognitive functions. Scientists are exploring “neuroprotective” treatment strategies to shield nerve cells from damage and death.

APOE

ApoE (apolipoproteinE) is the most significant genetic risk factor for late-onset Alzheimer's disease, with one variant—ApoE4—increasing a person's risk by up to 20 times the normal population. Scientists are investigating several strategies to modify this genetic risk.

RONALD CRYSTAL, MD
GREG PETSKO, DPHIL

WEILL CORNELL MEDICAL COLLEGE

Can we modify our risk of developing Alzheimer's disease? Ronald Crystal, MD, thinks there's a good chance we can. Like Dr. Hyman, Dr. Crystal—along with his colleague Greg Petsko, DPhil—is investigating APOE2 gene therapy.

"The problem is figuring out how to get APOE2 to the brain," explains Dr. Crystal. "Gene therapy is essentially a drug delivery device. Instead of using a protein, we're using the gene as a drug and a virus as a Trojan horse to deliver the gene to cells." Dr. Crystal, Dr. Petsko, and their team are working on a viral vector to deliver APOE2 directly to the brain. With funding from the ADDF, they are beginning preparations to manufacture the viral vector and create the data and documentation necessary to fast-track the project to human clinical trials.

"It is fantastic that the ADDF is supporting research like this."



BRADLEY HYMAN, MD, PHD
HARVARD MEDICAL SCHOOL
AND MASSACHUSETTS
GENERAL HOSPITAL

After more than three decades in Alzheimer's research, it's safe to say that Bradley Hyman, MD, PhD, has a wealth of experience in Alzheimer's drug discovery. He's equally well-versed in patient care, something that deeply informs his work in the lab. "I regularly see patients with this tragic illness," he says. "We need to help now."

Dr. Hyman is investigating APOE2 gene therapy for Alzheimer's disease. People with the APOE4 gene have the highest risk of developing Alzheimer's disease, while those with the APOE2 gene have a decreased risk. Gene therapy would use APOE2 as a treatment for people with the high-risk APOE4 gene. "We have an idea of how to take advantage of information about the genetics of Alzheimer's disease and a protective gene—APOE2—and turn that knowledge into a way to help patients," says Dr. Hyman. Research has already demonstrated that treating mice with APOE2 gene therapy can suppress the development of amyloid plaques characteristic of Alzheimer's disease.

With funding from the Alzheimer's Drug Discovery Foundation, Dr. Hyman and his team are evaluating the safety and therapeutic benefit of two different APOE2 viral vector approaches. "The ADDF has helped enormously," he says. "Our research is a little futuristic, and it is fantastic that the ADDF is supporting research like this."

You might be surprised to hear that Michela Gallagher, PhD, is on sabbatical. So what is she doing with all of her "free" time? She's buckling down in the lab at AgeneBio in preparation for a Phase 3 trial of AGB101, a new treatment for early-stage Alzheimer's disease. Its work that she says wouldn't be possible without the Alzheimer's Drug Discovery Foundation's initial support in 2010.

"I don't know how we would have gotten started at AgeneBio without the ADDF," Dr. Gallagher says. "It was the bridge to a program that is still doing very well, and we're tremendously grateful to the Foundation for its continued support."

The ADDF has been unyielding in its enthusiasm for Dr. Gallagher's work, most recently investing \$900,000 to enable preparations for AgeneBio's upcoming Phase 3 trial of AGB101. The study will test the drug in patients with amnesic mild cognitive impairment (aMCI), the pre-dementia phase of Alzheimer's disease in which memory is worse than expected for a person's age. Most aMCI patients progress to Alzheimer's dementia within 7 to 10 years.

AGB101 is a proprietary formulation of low-dose levetiracetam, an FDA-approved treatment for epilepsy. In the upcoming study, patients with aMCI will receive just one-twelfth of the regularly prescribed dose of the drug given once a day.

Dr. Gallagher is hopeful that, if results are positive, AGB101 will be available to patients soon after. "It has the advantage of a relatively fast clinical pathway because the safety of the drug is known, and allows us to focus on demonstrating the potential for AGB101 to slow progression of aMCI and delay onset of Alzheimer's dementia," she says.



MICHELA GALLAGHER, PHD
JOHNS HOPKINS UNIVERSITY
AND AGENEBIO

"The ADDF's funding was so beautiful because it gave us the resources we needed to get [this project] going and ultimately allowed us to get funding from the NIH."

COGNITIVE ENHANCING

Alzheimer's disease is characterized by the loss of memory, abstract thinking and judgment, language and other cognitive deficits. Scientists are investigating cognitive enhancing drugs that improve cognitive performance, including memory, problem solving and daily function.

NEUROINFLAMMATION

Chronic inflammation in the brain can accelerate Alzheimer's disease and may be a trigger of the disease. Scientists are investigating drugs that protect against disease- and injury-induced inflammation while preserving normal inflammatory responses.

THOTA GANESH, PHD
EMORY UNIVERSITY

Thota Ganesh, PhD, believes Alzheimer's researchers need to shift their attention. "The majority of drug discovery efforts are based on only one hypothesis—that an effective Alzheimer's drug must target amyloid plaques. We need to focus on testing new hypotheses," he says.

Dr. Ganesh, an Alzheimer's researcher and assistant professor of pharmacology, is working on neuroinflammation. "The goal of my research is to find a compound that targets the EP2 receptor [which appears to drive inflammation in Alzheimer's disease] and works as an anti-inflammatory and neuro-protective agent on patients," he explains.

With funding from the ADDF, Dr. Ganesh is in the early stages of testing one of his leading drug candidates in animal models. If this preclinical trial is successful, he and the team at Emory University will begin to develop a clinically useful drug for humans.



PAOLO PEVARELLO, PHD
AXXAM SPA

Paolo Pevarello, PhD, knows what Alzheimer's can do to families and caregivers. He's experienced the effects of the devastating disease within his own family. But as the principal investigator of Axxam SpA, an Italian biotechnology company, Dr. Pevarello is also uniquely positioned to fight it.

With continued support from the Alzheimer's Drug Discovery Foundation, Dr. Pevarello is making tremendous strides on that front. Since 2011, the ADDF has awarded Axxam three grants to further the company's research to identify drugs that selectively block the purinergic receptor, P2X7, which is involved in inflammation in the brain.

"In the last five years, there has been an increasing appreciation of the role that neuroinflammation plays in Alzheimer's disease," Dr. Pevarello explains. "The P2X7 receptor is pathologically over-activated with Alzheimer's."

That's why Dr. Pevarello is investigating drugs that selectively block the receptor and may be able to minimize brain inflammation. It's an area of research that, by and large, has remained largely unexplored.

Dr. Pevarello and the Axxam team are currently optimizing leading drug candidates. As he explains, "We're close to providing a proof-of-concept for our leading drug candidates, which will allow progression through the preclinical path to a clinical candidate."

Ultimately, Dr. Pevarello hopes that one of his drugs will be part of the solution to the Alzheimer's crisis. "Alzheimer's disease is a complex pathology and it's hard to think that a single 'magic bullet' will resolve it," he says. "Combining two or more complementary approaches, which are currently under evaluation, may speed up the pace toward its cure."

"We know so much about Alzheimer's disease—the opportunity to develop a drug is there."



GARY GIBSON, PHD
BURKE REHABILITATION CENTER

What if a treatment for Alzheimer's disease was already in your medicine cabinet? If Gary Gibson, PhD, is right about his drug—which is a close cousin to vitamin B1 (also known as thiamine)—that might not be far from the truth.

Dr. Gibson's compound, benofotiamine, works by raising and maintaining thiamine levels. Developed in Japan just after World War II, benofotiamine is more effective than traditional vitamin B1 supplements at increasing thiamine levels.

All patients with Alzheimer's experience a reduction in their glucose metabolism, a process that is dependent on vitamin B1. Dr. Gibson believes thiamine therapy may "have a large impact on Alzheimer's disease."

The evidence for his hypothesis is mounting. benofotiamine has already proven effective in animal models of Alzheimer's disease and safe in a double-blind clinical trial in Germany.

Next up: a Phase 2 clinical trial of benofotiamine in patients with early-stage Alzheimer's disease funded by a partnership between the Alzheimer's Drug Discovery Foundation, Burke Rehabilitation Hospital and the National Institutes of Health (NIH).

If the results of this study are promising, the formulation—which is already being manufactured by a safe and well-regarded facility in Canada—could be available to patients rapidly.



ENERGY UTILIZATION

All cells need energy to maintain healthy function, and brain cells are among the highest energy users. Because energy inefficiency and loss in neurons is a hallmark of Alzheimer's disease, scientists are working to develop drugs that enhance the function of the energy powerhouses of cells, known as mitochondria.

HOW WE'RE DIFFERENT

The ADDF is the only venture philanthropy focused on funding drug discovery. The path to a cure for Alzheimer's starts with basic science into how the disease works. This information helps create tests to diagnose and assess Alzheimer's and gives us the targets for drug discovery and development to treat and cure the disease.

% FUNDING BY AREA

-  **Drug Discovery, Development & Clinical Trials**
Finding a cure
-  **Molecular Pathogenesis**
How the disease works
-  **Diagnosis & Assessment**
How to test for the disease and its progress
-  **Epidemiology**
Describing the impact of the disease on distinct populations
-  **Care & Support**
How the disease affects patients, caregivers and society

**2012–2014 data from The International Alzheimer's Disease Research Portfolio, a database developed through a collaboration between the National Institute on Aging, which is part of the NIH and the Alzheimer's Association.*



Alzheimer's Drug Discovery Foundation



Alzheimer's Research UK



National Institutes of Health (NIH)



Alzheimer's Association



Cure Alzheimer's Fund



United States Army Medical Research and Materiel Command



Alzheimer's Society UK



Centers for Disease Control and Prevention (CDC)



United States Department of Veterans Affairs (VA)

PARTNERS IN THE DEVELOPMENT OF A CURE

The Alzheimer's Drug Discovery Foundation puts a premium on partnerships. And we're proud to work with more than a dozen foundations, businesses and government entities worldwide, including our newest partner, the Harrington Discovery Institute.

Over 10 years ago, we began a relationship with the Association for Frontotemporal Degeneration (AFTD), one of our closest allies in the fight against Alzheimer's. After a decade of collaboration, the ADDF and the AFTD have jointly funded 24 unique drug discovery programs through grants totaling over \$2.7 million. In 2014, the AFTD and the ADDF awarded new grants to Charlotte Teunissen, PhD, VU University Medical Center Amsterdam, and Matthew Disney, PhD, of Scripps Research Institute. Dr. Teunissen is tackling one of the greatest challenges facing frontotemporal degeneration research—differentiating the two most common subtypes of the disease in patients. Dr. Disney is working to design a drug-like compound that prevents a toxic chain of events caused by a

genetic mutation, C9ORF72, which is responsible for the majority of familial cases of FTD and ALS.

"We're very proud of our long-standing collaboration with the ADDF," says Susan Dickinson, Founding Executive Director, AFTD. "By combining our resources, we have provided the scientific community with a deeper understanding of this understudied disease and given patients and caregivers hope for potential treatments." Nadine Tatton, PhD, Scientific Director, AFTD, adds, "This is really cutting-edge science, and I believe that we're supporting truly innovative approaches to drug discovery for Alzheimer's, FTD and related diseases."

The ADDF values all of our 2014 partners. We know that when we team up with other forward-thinking organizations, we increase our funding power and our collective expertise—ultimately ensuring that we find a cure for Alzheimer's and related dementias faster.



CELEBRATIONS OF HOPE

From fashion shows to science symposia, the Alzheimer's Drug Discovery Foundation's 2014 lineup of special events made one thing clear: there is hope on the horizon. Throughout the year, more than 1,000 ADDF supporters came together for 13 events that together raised more than \$5 million. Our allies gathered to learn more about Alzheimer's research, meet people grappling with Alzheimer's, honor advocates and scientists working toward a cure ... and celebrate our progress!



Leonard A. Lauder and Norah O'Donnell



Heidi and Tom McWilliams

EIGHTH ANNUAL CONNOISSEUR'S DINNER

Honoring Leonard A. Lauder
Sotheby's, New York City | May 1, 2014



Robert and Renée Belfer



Paula Zahn and Howard Fillit, MD



Dan Gasby and B. Smith

FIFTH ANNUAL FALL SYMPOSIUM & LUNCHEON

Honoring B. Smith
The Pierre, New York City | November 3, 2014

FOURTH ANNUAL GREAT LADIES LUNCHEON & FASHION SHOW
Honoring Pat Summitt
The Ritz-Carlton, Washington, DC | April 1, 2014



Andrea Mitchell, Leonard A. Lauder and Elise Lefkowitz



Pat Summitt and Michelle Marciniak



DONOR SPOTLIGHT: ROBERT J. APPEL

Andrew Carnegie famously said, "The man who dies rich, dies disgraced." Robert J. Appel is guided by this same spirit of philanthropy. Mr. Appel explains, "It's not just about giving back, but about being active and involved."

Mr. Appel, who joined the ADDF's Board in 2015, is a leader in supporting medical research. He chaired his alma mater Cornell University's immensely successful campaign for Weill Cornell Medical College. And he and his wife recently established the Helen & Robert Appel Alzheimer's Disease Research Institute there. Though the disease hasn't affected their family, the Appels have lost close friends to Alzheimer's. He chose to get involved with the ADDF because: "The problem is complex, and the solution is going to come from research into new drugs. We have to approach the search for a cure from as many ways as we can."

Mr. Appel's charitable endeavors go beyond medicine. His love of early American music led him to become Chairman of the Board of Jazz at Lincoln Center. He also serves as Trustee Emeritus and Presidential Councillor for Cornell University. His generosity and hard work in support of nonprofit organizations is a wonderful example of the power of philanthropy.

THANK YOU FOR MAKING IT ALL POSSIBLE!

We are deeply grateful to all those who supported our work in 2014. Your generosity gives us hope for a future without Alzheimer's disease.

Over \$1,000,000

Anonymous

\$100,000 to \$999,999

Anonymous (5)
Alzheimer's Society UK
Helen and Robert J. Appel
The Association for Frontotemporal Degeneration
The Charles Evans Foundation
Katherine B. and Michael I. Colby
The Estée Lauder Companies Inc.
Julie and Philip H. Geier
Nancy and Melvin R. Goodes
Intra-Cellular Therapies, Inc.
The Lauder Foundation
Jo Carole and Ronald S. Lauder
Elise and Marc D. Lefkowitz
Leslie and Roslyn Goldstein Foundation
Georgia Melenikiotou-Garinois and

Philippe Garinois
Prana Biotechnology Limited
Ray and Dagmar Dolby Family Fund
Robert A. and Renée E. Belfer Family Foundation
Liz and Randal B. Sandler
Sotheby's

\$50,000 to \$99,999

A.P. Kirby, Jr. Foundation, Inc.
Cynthia Breen and Laurie A. Dowley
Paddy Ann and Latham Burns
Nancy Corzine
Nancy and Steven Crown
Evelyn and Lynn de Rothschild
Anne B. and Joel S. Ehrenkranz
Bruce S. Gelb
Judy Glickman Lauder
Laura and Gary Lauder
William P. Lauder
Bonnie Englehardt Lautenberg

Dalia and Laurence C. Leeds
Dan Lufkin, The Peter Jay Sharp Foundation
National Institutes of Health
Lois Robbins and Andrew Zaro
Betsy and William F. Ruprecht
Nathan E. Saint-Amand
Susan and Peter J. Solomon
Joan Sutton Straus
Carol and Michael Weisman

\$25,000 to \$49,999

Toby and Ronald A. Altman
Carol Seabrook Boulanger
Rose Marie Bravo and William Jackey
Zoe and William D. Budinger
Melanie and Louis Caceres
Caryn J. Clayman
Michael T. Cohen
Condé Nast Publications
Cures Within Reach
Donnelly Mechanical
Annette and Mitchell D. Eichen
Ernst & Young, LLP
Marilyn and Sam Fox
Dina Merrill Hartley and Ted Hartley
Susan and Roger Hertog
Ronnie F. Heyman
David H. Komansky

Lilly USA, LLC
Beatrice Liu and Philip H. Lovett
Susan Lloyd
Macy's and Bloomingdale's
William E. Mayer
Merck Research Laboratories
Shelah and Marc Moller
Neurotrax Corporation
The Northern Trust Company
Nucor Construction
Thomas Pheasant
The Ralph and Ricky Lauren Family Foundation, Inc.
Trish and Steven J. Shapiro
Staples Advantage
Teauman and Grace Fuite Foundation
Tishman Speyer Properties, LP
US Trust, Bank of America Private Wealth Management
Paula Zahn
Alison and Buzz Zaino

\$10,000 to \$24,999

Anonymous
Pennie and Gary Abramson
Jennifer and Claude Amadeo
Judy and John M. Angelo
Placido Arango
Claire and Daniel S. Bernstein

BET Networks
Beyond Batten Disease Foundation
Merilee and Roy Bostock
William K. Bowes
Estrellita and Daniel Brodsky
Bobbi Brown and Steven Plofker
Linda and Arthur L. Carter
Maureen Case and Victor Fuentes
Children's Tumor Foundation
Russel M. Cox
David A. Deckelbaum
John D. Demsey
Faith and Warren Diamond
Valerie and Charles M. Diker
Marti and Robert Dinerstein
First Republic Bank
Ann B. and Thomas L. Friedman
Barbara and Richard I. Furman
Marlene Hess and James D. Zirin
Rita and Peter Heydon
Joanna Horgan
Horizon Media
Amy and Mitchell Kaneff
The Kaneff Foundation
June E. Kay
Dana H. and Brian C. Lawlor
Margaret and Daniel S. Loeb
Michelle MacDonald
The Marc Haas Foundation, Mr. and

Mrs. Stanley Shuman
Carlyn Sundberg McCaffrey
PepsiCo Foundation
Pfizer Inc.
Sharon and Robert Prince
Joan Rall
Robert A. Saccaro Foundation
Hilary and Wilbur L. Ross
Ophelia and William C. Rudin
Sharon T. Sager and J. Loring Swasey
Karen and Nathan Sandler
Joan and George W. Schiele
June and Paul C. Schorr
Carole and Gordon Segal
The Sheldon H. Solow Foundation
Larry Silverstein
Barbara Solomon, Fross Zelnick Lehrman & Zissu
Jennifer and Mark Styslinger
Mary Rose Taylor
Ann and Andrew Tisch
Barbara and Donald G. Tober
University of Pennsylvania
USAgainstAlzheimer's Network
Trish and George Vradenburg
Giselle F. Wagner and Paul A. Myerson
Harriet and Ronald Weintraub
Kimba Wood and Frank E. Richardson

Mortimer B. Zuckerman
\$5,000 to \$9,999
Anonymous
Acquavella Family Foundation
Patricia M. Altschul
Alzheimer's Association
Roberta Amon
Shelley and Robert Banks
Renee Berger
Tina and Simon Beriro
Biogen Idec
Isabelle and Scott M. Black
Alecia and William Blake
Nancy and Robert S. Blank
Rochelle and Bernard Bloom
Bloomberg LP
Faith Bobrow
Susan S. and Richard S. Braddock
Evelyn and Lawrence N. Brandt
Jill and Daniel Brigati
Buffy Cafritz
Lynda and Davis Camalier
Canada Loves New York
The Charmer Sunbelt Group
Jacque and William E. Connor
Douglas DiPasquale
Cherrie Doggett
Beth and Ronald Dozoretz

Valerie Elia
Susie and Edward E. Elson
Suellen Estrin
Sandi and Andrew Farkas
Betty and David C. Farrell
Phebe Farrow Port
Father's Day/Mother's Day Council, Inc.
Elizabeth J. and Niall M. Ferguson
Forest Laboratories, Inc.
David Gerson
Andrea and James A. Gordon
Marjorie Reed Gordon
GroupM
Dee and Thomas Hilfiger
Wendy Holmes
The Howard Johnson Foundation
Jane and Clifford Alan Hudis
Lynette and Richard Jaffe
Kiera and Christopher Johnson
Eleanora R. and Michael John Kennedy
The Lawrence Ellison Foundation
Harriette and Noel Levine
Linda G. and Steven Levy
Kate and Charles T. Lindsay
Lord & Taylor
Kristen L. and George Lund
Carol and Earle I. Mack

Holly Madigan	Sarah and John F. Walsh	Bachem Americas Inc.	Lois Chiles and Richard Gilder	Barbara Fields	Shirley and Barnett Helzberg	Foundation, Inc.	Brooke and Daniel M. Neidich
Mayo Foundation for Medical Education and Research	Lulu Chow and Anthony W. Wang	Rachel Balsam	Cynthia Clift and David Wassong	Howard Fillit, MD	Michele and Lawrence Herbert	Laurie M. Tisch Illumination Fund	Neiman Marcus Group, Inc.
McDonald's Restaurants Limited	Catherine J. Webb	James Bartholomew	Chuck T. Close	Kate Ford and Frank Chopin	Catherine J. Hirsch	Gretchen and Howard H. Leach	Newport Painting & Decorating
Sara E. Moss	Charlotte C. Weber, Live Oak Foundation	Mercedes T. Bass	Lisa Cohen, Philadelphia Financial Management of San Francisco	Georgia and Ronald L. Frasch	Agnes Hsu-Tang and Oscar L. Tang	Karen and Richard S. LeFrak	New York Stem Cell Foundation, Inc.
National Multiple Sclerosis Society	Wheels, Inc.	Bed Bath & Beyond, Inc.	Marcy and Neil Cohen	Mary Ann and Fabrizio Freda	Ann Marie Huebner and Ross P. Waller	Susan Lehrman	Melanie and Lawrence Nussdorf
Pamela J. Newman	Wendy Wilshin and Ronald Dickerman	Sandro Belvedere	Jeanne Coleman	Carolee Friedlander	Denise M. and John J. Hyland	Thelma and Melvin Lenkin	Oryzon
Keith Nickels	Elaine and James D. Wolfensohn	Candice Bergen and Marshall Rose	CVS Caremark	Lacy and Ernie Fyrwald	IDSC	Pierre Levai	Lisa L. and Mehmet C. Oz
Kate and Robert H. Niehaus	Wyndham Hotel Group	Barbara and Bruce Berger	Cyprotex Discovery Ltd.	Veronique Gabai-Pinsky	InterVivo Solutions Inc	Toby Lewis	Alex Papachristidis
Terri and Steven H. Oram	Deborah Miller Zabel and William Zabel	Clifford Berger	Norma T. Dana	María T. Galeno	IRBM	Peter B. Lichtenthal	Partners Healthcare
Eileen and Leonard Palevsky	Linda S. Zambelli	Wilma E. and Stuart A. Bernstein	The David and Karen Pecker Foundation	Genentech USA	Judith Jackson and Bruce D. Haims	Serena and John Liew	Susan and Alan J. Patricof
PFDL Investments Limited	Virginia and Robert B. Zink	Myra and Charles Biblowit	Bonnie M. Davis, MD	Alma L. and Joseph B. Gildenhorn	Jill Heller Fine Jewelry Corporation	Susan and Martin Lipton	Josie Patton
Kathleen R. and Michael J. Pierce	\$1,000 to \$4,999	Biosensis Pty Ltd	Barbara de Portago	Sondra Gilman and Celso Gonzalez-Falla	Cindy Jones	Leonard D. Litwin	Elizabeth and Jeffrey M. Peek
Pauline Pitt and Jerry Seay	Anonymous (3)	Frank J. Bisignano	Robert de Rothschild	Beth O. and James Kenneth Glassman	Margaret T. and Bolton Jones	Carol L. and Eugene A. Ludwig	Sharon Percy and John D. Rockefeller
Kelli and Allen Questrom	Madlyn and Leonard Abramson	Victoria Bjorklund	Tanvi K. and P. Bobby Dey	Mildred and Arne Glimcher	Vernon E. Jordan	William Mack	Karen and Brian Perlman
Margaret Rice	Katherine and Paul S. Adler	Steven L. Blacher	Kevin J. Dieterich	David Goodes	Judy & Howard Berkowitz Foundation	Sandra Main	Marsha Perreault
Denise Rich	Dena L. Henry and John Ahern	Lynn and Wolf Blitzer	Amy DiGeso and Paul Rakowski	Jane Mack Gould	Kasper	Dobra and Bennett Marshall	Cynthia Hazen Polsky
Lita Rosenberg	Alexandria Real Estate Equities, Inc.	Emmie and Herman Bolden	Frank L. Doyle	Lynne Greene	Mariana and George S. Kaufman	Alison McCall and Peter Eliel	Laura H. and John Pomerantz
Janet C. Ross	Ally Financial	Jeannine Bouillier-Siegmund	Caroline and Howard Draft	Laurie B. and Philip M. Gross	Karen A. and Kevin W. Kennedy	McGraw Hill Financial	Alma and Colin L. Powell
Susan and Jack Rudin	Tina Alster, MD	Brains On-Line	Sean Driscoll	Audrey and Martin D. Gruss	Janet W. Ketcham	Joanie and Andrew McKenna	PsychoGenics, Inc.
Patricia Bennett Sagon	Jean M. and Timothy J. Alvino	Laura Louise Breyer	Nancy E. and Marc N. Duber	Agnes Gund	Zoe and Shaker Khayatt	Robin R. and Dennis McNeill	QPS
Victoria and Roger W. Sant	The American Hotel	Mildred Brinn	Jacquelyn Fain Duberstein and Kenneth Duberstein	Sharon Handler and John L. Loeb	Karyn A. Khoury and Stephen Kopach	Anita J.H. and Sam Michaels	Liam Ratcliffe
Jeanette Sarkisian Wagner and Paul A. Wagner	Ann and Steven Ames	Donald L. Bryant	Eckert Seamans Cherin & Mellott, LLC	James E. Hanson	Phyllis L. Kim	Elaine and William A. Miller	Clayton S. Reynolds
Debbie and Craig R Stapleton	Gloria and Kim C. Anderson	Jackie and John Bucksbaum	Deborah Epstein	Jacqueline and Daniel G. Harman	Sidney Kimmel	Sheila and James N. Mills	Karen and Lewis Rice
Philip E. Stieg, M.D.	Richard Aneser	Henry Buhl	Stuart M. Fain	Jane Harman	Diana and Israel Kogan	Fern and Alfred H. Moses	Ricerca Bioscience
Alexandra C. Trower and Jon Lindsey	Ariel Investments, LLC	Frances K. and Leonard W. Burka	Raysa M. and Alfonso J. Fanjul	Harman Family Foundation	Michele and Kevah Konner	Linda and Sidney Moskowitz	Sheila Johnson Robbins
University of Kentucky		Bari Burman		Chris Harris	Deborah and Peter Krulewitch	Charlotte Moss and Barry Friedberg	Aviva and Jack A. Robinson
Rebecca and Michael Voslow		Josh Cammaker		John Hart	Carol H. Launer	Sara Moss and Michael Gould	Paula and Leon Root
		John K. Castle		Vivien and Alan G. Hassenfeld	The Laura Steinberg Tisch	Anne W. and Charles Mott	Susan and Elihu Rose
		Cellular Dynamics International				Mulé Family Foundation	Nancy and Miles Rubin

Kevin M. Ryan	Stephen P. Wald Real Estate Associates	Faruk Abuzzahab Sr.	Debra L. and Edward L. Cohen	Margaret T. and Thomas H. Hall	John Kossow	David Moscow	Robyn Shepherd and Alex Drolet
Stephen I. Sadove		Lise Adkins	Carole Cooper and Richard Leibner	Eric Hangen	Elizabeth S. Kujawski and Tom Zoufaly	Jamie Mullen	Shirley S. and Albert H. Small
SAGE Labs	Shiyami and Aravinth I. Siva Subramaniam	Susan W. Agger and Richard Budson	Jamie N. Cooper	Harrington Discovery Institute/ Biomotiv	Eileen and Richard W. Kunes	Bettye Musham	Lisa and Denis Somar
Thomas Sandell		Mary Pat and Darren Alcus	Lizette Corro	Ellen R. Harris	Dana Landow	Neiman Marcus Mazza Galerie	George A. Sorial
Leslie and Richard L. Sandler	Taconic	American Express	Alexandra de Borchgrave	Elizabeth Hefferon	Amy B. and David Liebowitz	Ellen Newman	Jill Gloria Spalding
Sanguine	Taub Institute for Research on AD and the Aging Brain	Karen Amo	Robert de Jonge	Laurie F. Heflin	Charlotte and Morvin Leibowitz	William Newsome	Stephanie Spinola
David T. Schiff		Peter J. Anderson	William G. Dessoify	Sabrina and Marco W. Hellman	Pierre Lestage	Jun Nishiu	Bonnie Staffier
Carol and Lionel H. Schipper	Judith and A. Alfred Taubman	Eleanor Fulcher Arnold	Rosie Donahower	Michael Hendrickson	Lawrence Luebcke	Ann K. and William Albert Nitze	Linda Stargatt and Lawrence P. Mann
George J. Schmitt	Felicia Taylor	Jan Aronson	Julie Douville	Pamela Henes	Linda and Harry Macklowe	Vita Pagnani	Sue and Michael Steinberg
Daria A. and Mitchell Schrage	Daniel Termini	Patricia Assatly	Gayle I. and John G. Engel	Ken C. Hicks	Hildegarde Mahoney	Hannah Pakula	Margaret Stouffer
Barbara Schwartz	David Tillson	Barbara and Gerson Bakar	Steven English	Barbara and Gerald Hines	Marlene and Frederic V. Malek	Courtney Pastrick	Bonnie and Thomas W. Strauss
Martin Schwartz	Robert Towbin	Eileen Bakke	Mary C. Farrell	Diane Hockstader	Ekaterini Malliou	Allison Perlmutter	T. Rowe Price Foundation, Inc.
Hadley and John H. Scully	Tracey T. and Richard Travis	Jamie Baldinger	Amy J. and Robert A. Feinblatt	Richard Hoffman	Susan Malloy	Jacqueline L. Pletcher	Vicki and Harold Tananbaum
Bari D. Seiden	United Way Ottawa	Eve and Francis Barron	Barbara Fleck	John Holland	Ellen Marks	Shilpi Prasad	Karen Tandy
Aruna Seth	Eunice C. Valdivia	Caryn Seidman Becker	Debbie Forrest	Richard Holub	Shirley Maytag-King	Inez N. Richardson	Neil Thompson
Finley and Patrick Shaw	Lauren and John Veronis	Leonard J. Bencivenga	Jennifer L. Franklin and Scott Hall	Ivy Howells	Melody McDonough	Molly Robb	Judith and Michael Thoyer
Nancy and Charles Shoemate	Bette and Martin von Haselberg	Michele G. and Allan J. Berman	Gay and Stanley N. Gaines	Cathy and Walter Isaacson	Lyn and Mark McFadden	Anne Rojas	Annie S. Totah
Nancy Slomowitz	Sandra and Stanford S. Warshawsky	Michael Blonar	Robin and Todd Galkin	Judy and Verne G. Istock	Paige and Bart McKenzie	Shirley Lord Rosenthal	Truist
Tina B. and Albert H. Small	Sue Ann Weinberg	Yuval Blat	Samuel Gandy	Rosalind G. Jacobs	Ann McLaughlin and Thomas C. Korologos	Sarah Rothman	United Way of Greater Toronto
Karen and Spencer G. Smul	James White	Fabienne and Patrick Bousquet-Chavanne	Min Gao	David Jacobson	Richard Meier	Adam Rowe	Sahba Vaziri and Ali Reza
Ann and Richard H. Solomon	Carolyn and Malcolm H. Wiener	Amy Branch	Barbara J. and Ronald M. George	Jill's Cookie Cart LLC	Jennifer and Brad J. Melvin	Connie and Peter Ruben	Irene E. and Lawrence Waxman
Joan and Gavin Solotar	William and Jacqueline Shaw Family Foundation, Inc.	Joanna Breyer	David Gladstone	Marissa T. Johnson	William O. Melvin	Sara A. and Paul S. Russell	Marcia and Robert Waxman
Maurice Sonnenberg		Daniela Brunner	Edith Goldberg	Violeta Jordan	S. Epatha Merkerson	Lisa and Sal Salibello	Molly and Peter Weinberger
Alicia A. Sontag	Adrienne and Robert Zarnegin	Bettina Bryant	Ellen and Ian Graham	Jayne T. Keith	Paul Metselaar	Ellin Jane Saltzman	Christie Weiner
Soros Fund Charitable Foundation	Irene and Carl Zelinsky	Pauline Calomiris	Sylvia Greenberg	Victoria E. and Patrick C. Kelly	Judith L. Mogul	Evelyn Sandground and Bill Perkins	Constance C. and Arthur C. Weisenseel
Constance and Stephen Spahn		Iris Cantor	Jane Greenwald and Lawrence A. Wein	Eileen and John Kim	Robert Morrison	Frances G. Scaife and Tom McCarter	Andrea Weiswasser
Barbaralee and Carl Spielvogel	\$500 to \$999	Amy and Gordon Caplan	Sara Greenwood	David Kossor	Enid and Lester S. Morse	Edith F. and Gerald H. Schaeffer	Westminster Canterbury
Lisa B. Spikell	Able Cerebral, LLC	Anne-Marie Chollet	Susan and John H. Gutfreund			Nancy Seltzer	Carol and Michael Winer
Judy and Michael H. Steinhardt	Patty Abramson					Leslie Shapiro	

Michael Wolfson	Paul Coleman	Helen Freifeld	Ira M. Resnick Foundation, Inc.	Alan M. Mendelson	Ashish Raj	Marla and Thomas Sinchak	Martin Williams
Helena Wong	Robyn and William M. Collins	Laurie Friedman	Catherine Jackson	Mary Louise and Elias K. Michaelis	Chongzhao Ran	Carol and David Sinclair	Manfred Windisch
	Carol A. Colton	Marisa L. and Ross S. Friedman	Lisa Jobe	Jacqueline Michel and David Weissman	Natalie Rasgon	Ambuj Singh	Paula and Alan Wiseman
\$250 to \$499	Joanne Contopoulos	Anders Fugelli	Lady Barbara Thomas Judge	Catherine Miller, College of Law	Larry Refolo	Andre Spearman	Eric Wittenberg
Benedict Albensi	David Corbin	Scott H. Gamber	Amal Kaddoumi	Jennifer Miller and Mark Ehret	Dorothy Elizabeth Reifenheiser	William Squier	Stephanie and Christian Wollny
Jane and David Atkins	Michael J. Corcoran	Darby E. and J. Montgomery Gingery	Nancy Katz	Virginia A. Millhiser	David Resnicow, Resnicow Schroeder Associates, Inc.	Martine and James A. Stamos	Joseph Yurcik
Martin Auerbach	Linda V. Courie	Susan Goldberg	David Kemp	John Millyard	Nancy F. and Gary N. Reynolds	Stephen M. Stay	Laura and Shariar Zaimi
René Augustine and Mark Alarie	Maria Crowley	Barbara and Robert Goldfarb	Anne and Robert Kiely	Judy Minor	Diego Rincon-Limas	Maxwell Stock	Yvonne Zoomers
John Avery	Lisa B. Crupi	Geoff Golding	Kevin Kitt	Liat Mintz	Robert Derector Associates	Benita Stokes	
AWA Family Foundation	Mary H. and Myron P. Curzan	Goldman Sachs & Co. Matching Gifts Program	Carol Klein	Triana M. and James Moe	Lexi Rodriguez	Joan A. Stone	IN KIND GIFTS
Susan and Joel Bell	Maureen Dalton	Jane and Richard D. Grant	Carol and B. Erik Knudsen	Judith L. and Mark Morris	Janet Rogozinski	Leslye and Fred Sugar	Abrielle Fine Linens and Lingerie, Inc.
Sarah Bendit	Dattner Architects	Mark Gurney	Peter O. Lawson-Johnston	Julie and William Obering	Stacey Rosenthal	Patti Sullivan	Tina Alster, MD
Andrew M. Blum	Corinne Davidov	Jennifer Haber	Valerie Lederberg	Deb O'Hara-Rusckowski	Katy Sadeghian	John S.M. Svendsen	Amaryllis, Inc.
Justin Boyd	Eliot Davidowitz	PengCheng Han	Marie and Leighton Lee	John Osth	Saks Fifth Avenue	Francesca Tedesco	Balance, Your Pilates, Yoga & Gyrotonic Studio
Karen and Mitchell Brand	Sandi A. Davidson	Lori and Khaled T. Haram	Mary Joe Lent and Juan Salgado	Steven Padgett	Hasib Salah-Uddin	RJ Tesi	Rochelle and Bernard Bloom
BrightFocus Foundation	Barbara and Ronald Demczak	Madelyn C. Harris	Daniel Levesque	Koula K. and Thomas N. Papadopoulos	Rosita Sarnoff	Bradley Thayer	Bobbi Brown Cosmetics
Brighton Jones, LLC	John Didsbury	Alexandra Hartenbaum	Barbara and Harvey Levinson	Jack Pasini	Sandra L. and Lowell F. Satler	Julia Tolkan	Bumble and bumble.
Lori H. Bubes	Joyce and David N. Dinkins	Melissa Hawks	Wencheng Liu	Louise and Paul Pesale	Susan and Gerald S. Savitsky	Theodore Torphy	Café Milano
Nancy and Alan Bubes	Jamie Dorros	Susan C. and Robert M. Hayes	Stacey and Greg Lubar	Suzana Petanceska	Pat Schoenfeld	Caroline and Albert H. Turkus	Chelsea Piers
Nora Burke	Silvia and Peter Dreyfuss	Joan L. Hayman	Joyce F. Luchtenberg	Pfizer Foundation Matching Gifts Program	John Seabrook	University of Maryland Athletics	Colliers International NYC LLC
Joanne Butler	Barbara Eager	Jody and Andy Hecht	Elizabeth H. Lufkin	Miri Polachek	Alan D. Seget	Vasiliki and John L. Valanos	Stacey Cooper
Nigel Cairns	Diana and Stephen Elkin	Janne Heifetz	Patricia Lunka and Gary Lunka	Diane and Edward A. Powell	Jul Lea Shamy	Mike Vitek, PhD	Nancy Corzine
Hilary P. and Joseph A. Califano	Susan Emanuel	Linda and Dennis A. Herman	Gladys Maestre	Teddy Puschkarski	Paul Sherrill	Molly Wagster	Daniel
CanadaHelps	Shane Evans	Robert M. Higdon	Carolyn B. Maloney	Jay Radin	Nayun Shin	Loretta and Charles F. Walz	dell'anima
Susan Chapman	Marjorie Everitt	Robert Hillman	Suzanne and Michael M. Maney	Leslie and J. Andrew Rahl	Lauren Shortt	I-Fan Wang	Dempsey & Carroll
Alina Cho	Joseph Farley	Beth A. Hollister	Vivien K. Marion	Katherine L. and Edward J. Railey	Lois Siegel	Deb and Bernie Weiss	Design Cuisine
Judith G. Churchill	Jose Fernandez	Kristin Huber	Kathleen and Chris Matthews		Deborah Sigmund	Elizabeth and Walter Welsh	Allison Diener Perlmutter at Deiner Jewelers
Joy W. and S. Robert Cohen	Kathryn Fleischer	Raeanne Hytone	Wendy and Daniel McGrath		Patricia Silver	Allicia Wertheim	
Robert Colacello	Linda N. and Jay Weil Freedman		Laura McIntire			Tina West, MD	

elan Indique
 The Estée Lauder Companies Inc.
 Fiola da Fabio Trabocchi
 First Republic Bank
 Four Seasons Hotel Washington, DC
 Fourth Wall Restaurants LLC
 Gillies Coffee Company, Brooklyn
 New York
 Anya Hindmarch
 Jenny Ng Designs
 Jill's Cookie Cart LLC
 JRINK JUICERY
 Dorothy Bush Koch
 Kurent Events Catering
 Linda Landaw
 Elise and Marc Lefkowitz
 The Mayflower Grace
 Metrokane—a Division of Taylor
 Precision Products
 Michael's Restaurant New York
 NBCUniversal
 Thomas Pheasant
 The Phillips Collection
 Prestige Beverage Group
 Rasika West End
 The Ritz-Carlton New York, Central
 Park
 The Ritz-Carlton, Washington, DC
 Robin Labb Jewelry

Sharon T. Sager
 Saks Fifth Avenue
 Sirio Ristorante
 The Spa at the Peninsula New York
 Stoli Group USA
 Teuscher Chocolates of Switzerland
 Andrew Turk
 Washington Nationals
 Tina West, MD / The West Institute
 Warby Parker
 Wölffer Estate Vineyards

IN MEMORY

We remember all those taken by Alzheimer's in 2014 by continuing to fight for a cure.

Margaret Louise Ashburner	Chauncey Lufkin, Jr.
Jacques Boulanger	Jack Mausner
Marie Hunan Brennan	Charles Minichiello
Edward Carney	Eloise Mondau
Melvin R. Clayman	Jose A. Nessim
Betty King Culbreath-Gibbons	Mary Maughan Patton
Willis Denekas	Esta L. Poole
Louis DiPasquale	VS Ramalingam
Lev Dobrovinskiy	Doris Ray
Russell Eugene Edwards	Dorothy Willison Reed
Bernice Elkin	Rebecca Ritchie
William M. English	Ron Schick
Beatrice Fey	Rosina Silla
Jonathan E. Franzblau	Evelyn Singer
Leon Gilbert	Gertrude Sokol
James Grant	Sonny Spears
Marilyn Harvey	Amelia Ubina
Sally Hokanson	Francis J. Webb
Luisa Juncosa	
Joanne Ladd	

IN HONOR

In 2014, many generous gifts were made to the Alzheimer's Drug Discovery Foundation in honor of friends and loved ones.

Jessie Agosto	Irene Friedman	Elaine and Bill Miller	Amelia Ubinar
Sharon Anderson	Abraham Gelber	Nancy Corzine Interiors	Jordan Via
Shelley Banks	Maria Giannissis	S.I. Newhouse	Mollie Wein
Jerald Barnett	Phyllis Gingery and Ruth Brateng	Dorothy Oliverio	Lenny Witowski
Isabelle Black	Nancy and Melvin R. Goodes	Eileen Palevsky	Mike and Grace Yalich
Rochelle and Bernard Bloom	Louis James Goodman	Richard Pearman	The Yuengling Family
Faith Bobrow	Robert Gotkin	Rasika West End	
Carol Boulanger	Carol Gruber	Dolly Reed	
James Lewis Bragg	Flora Guglielmino	Phoebe Rice	
Jean Brigati	Chelsea Guida and John Temm	Jacqui Rosshandler and Matthew Dicker	
Ben Burke	Frank and Theresa Hargrave	Janice Rudbart	
Eileen Caprio	Pauline Harris	Polly Runyon	
I-Ling Chow	Christopher Johnson	Sharon Sager	
Phyllis Coffin	Susan Katzke	Jackie Sandler	
Antonio Coppola	Sophia Kay	Randal Sandler	
Amiee Darling	Betty Keegan	Jeannine Bouillier Siegmond	
Albert Dvorkin	Rachel Lane	B. Smith	
Betty Farrell	Leonard A. Lauder	Joan Sutton Straus	
Howard Fillit, MD	Laurence Leeds	Joan Taylor	
Sue Finnell	Vivienne Malba		

2014 FINANCIAL OVERVIEW

STATEMENT OF FINANCIAL POSITION

ASSETS	12/31/14
Cash and cash equivalents	
Operating	\$ 4,633,217
Restricted	274,468
Cash held by related party	15,640
Total cash and cash equivalents	4,923,325
Investments, at fair value	10,809,963
Contributions receivable	4,059,717
Due from Institute for the Study of Aging	133,215
Other assets	26,103
Total assets	\$ 19,952,323
<hr/>	
LIABILITIES AND NET ASSETS	
Liabilities	
Accounts payable and accrued liabilities	\$ 49,324
Grants payable	11,513,136
Deferred revenue	61,350
Total liabilities	11,623,810
Net assets	
Unrestricted	8,054,045
Temporarily restricted	274,468
Total net assets	8,328,513
Total liabilities and net assets	\$ 19,952,323



STATEMENT OF ACTIVITIES

CHANGE IN NET ASSETS	12/31/14
Support and Revenues	
Support	
Contributions and grants	\$ 6,514,722
In-kind contributions from the Institute for the Study of Aging, Inc.	2,832,504
Proceeds from special events, net of direct expenses	2,818,092
Revenues	
Grant Returns	1,799,905
Conference registration fees and other income	226,173
Investment and other income	1,574
Foreign exchange gain	105,048
Total support and revenues	14,298,018
Expenses	
Program services	10,850,140
Fundraising	1,236,175
Management and general	493,156
Subtotal	12,579,471
Expense for uncollected pledge	925,000
Total expenses	13,504,471
Change in net assets	793,547
Net assets, beginning of year	7,534,966
Net assets, end of period	\$ 8,328,513

RESOURCES

The Alzheimer's Drug Discovery Foundation is committed to providing researchers with the tools they need—from research funding to connections with drug discovery experts—to further their drug discovery efforts and advance the global search for an effective treatment, and a cure. While we continue our work toward ending Alzheimer's, the team at the ADDF is also evaluating the science behind prevention strategies to help you lower your risk.



SCIENTIFIC CONFERENCES

Our scientific conferences promote the exchange of ideas, the sharing of research results and the formulation of strategic alliances to further drug discovery and development goals. In 2014, we hosted two conferences, bringing together nearly 500 scientists, and co-sponsored and exhibited at many more. In addition to the conferences, we organized several advisory councils to identify solutions to specific challenges slowing the discovery and development of drugs to prevent and treat Alzheimer's, shared findings from these in white papers.

alzdiscovery.org/events/conferences

ADDF ACCESS

Drug discovery is a team effort, requiring collaboration between biologists, chemists, pharmacologists and many others. In 2014, ADDF ACCESS launched an enhanced online platform to help our research community of more than 4,500 scientists connect with a virtual network of consultants and contract research organizations (CROs)—connections that are critical to advancing their drug discovery work.


addfaccess.ondeckbiotech.com



PREVENTION

It's impossible to make educated decisions about brain health without access to the scientific evidence for and against potential strategies and treatments to prevent dementia. That's why this year our scientists launched Cognitive Vitality, a site designed to empower people to make smart, science-backed choices about brain health. The team behind Cognitive Vitality has conducted in-depth evaluations of 32 potential treatments to protect from dementia, ranging from FDA-approved drugs to natural products and supplements.

CognitiveVitality.org





Alzheimer's
Drug Discovery
Foundation

“TOGETHER WE CAN CONQUER ALZHEIMER’S DISEASE”

— Leonard A. Lauder & Ronald S. Lauder, Co-Founders & Co-Chairmen,
Alzheimer’s Drug Discovery Foundation

57 West 57th Street, Suite 904 | New York, NY 10019
P. 212.901.8000 | E. info@alzdiscovery.org | Alzdiscovery.org